Gaudium IVF IPO
Market Sentiment
IPO Details
Market Lot Size
IPO Reservation
Financial Analysis
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 44.26 | 48.15 | 70.96 |
| Expense | 25.95 | 31.52 | 45.54 |
| Profit (PAT) | 13.53 | 10.32 | 19.13 |
| Total Assets | 36.63 | 51.01 | 88.51 |
Promoters: Dr. Manika Khanna, Dr. Peeyush Khanna and Vishad Khanna
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 6,13,94,384 | 99.99% |
| Promoter Holding Post Issue | 7,27,86,884 | 71.30% |
Strengths & Risks
- Strongly subscribed — 7.3x overall (final).
- Revenue grew 47% in the latest reported year.
- Solid profit margin — 27.0%.
- Strong return on equity — 41%.
Our data checks haven't flagged a specific concern for Gaudium IVF — but that isn't a clean bill of health. Read the risk-factors section of the RHP, which lists company-specific risks our data can't capture.
Compiled from this issue's live GMP, subscription, valuation and financial data, and updated as those figures change. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Gaudium IVF, founded in March 2015, is one of the leading companies offering In Vitro Fertilization (IVF) treatments for women across India. The company operates its business over 30 locations, with seven hubs (centres) and twenty-eight spokes. The firm treats its patients in various countries, including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman. The firm offers various fertility services such as Vitro Fertilisation (IVF), intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), and ovulation induction. Its treatments are targeted towards both genders. Moreover, the firm also provides PCOD/PCOS, endometriosis, and special care for women in pregnancy with complex fertility issues. Gaudium IVF also offers treatments targeting male infertility, including advanced sperm retrieval procedures.
Gaudium IVF & Women’s Health Ltd., B1/51,, Janak Puri,, B-1,, New Delhi, New Delhi, 110058
| Purpose | Amount (Cr) |
|---|---|
| Funding capital expenditure towards establishment of New IVF Centers of the Company | 50.00 |
| Repayment/pre-payment, in full or in part, of certain outstanding loans availed by our Company; and | 20.00 |
| General Corporate Purpose | - |
Resources & Documents
Gaudium IVF has set a price band of Rs 75–Rs 79 per share for an issue size of Rs 165 crore. The stock listed with a 5.06% gain versus its issue price on February 27, 2026.
Gaudium IVF, founded in March 2015, is one of the leading companies offering In Vitro Fertilization (IVF) treatments for women across India. The company operates its business over 30 locations, with seven hubs (centres) and twenty-eight spokes.
The issue is promoted by Dr. Manika Khanna, Dr. Peeyush Khanna and Vishad Khanna with Sarthi Capital Advisors Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards Funding capital expenditure towards establishment of New IVF Centers of the Company (Rs 50 crore) and Repayment/pre-payment, in full or in part, of certain outstanding loans availed by our Company; and (Rs 20 crore).
On fundamentals, the company is posting revenue growth of 47.4%, a profit margin of 27.0%, return on equity of 41.3% in its most recent reported period.
On our data-signal score, the combined signals for this issue currently read mixed — some indicators read positively and others do not. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Gaudium IVF IPO GMP — What It Means
GMP stops mattering once the shares trade — it only ever estimated the listing price. The summary at the top of this page compares the last pre-listing GMP with how the shares actually listed.
See the full Gaudium IVF GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!